Related Experiment Videos
Efficacy and cost analysis of ibutilide
The Annals of Pharmacotherapy
|December 1, 2000
Summary
Ibutilide effectively converts atrial fibrillation and flutter, with 50% success and 67% rhythm maintenance. While costly for hospitals, it offers significant savings for third-party payers.
Area of Science:
- Cardiology
- Pharmacology
- Health Economics
Background:
- Atrial fibrillation (AF) and atrial flutter (AFl) are common arrhythmias.
- Effective and cost-efficient treatment strategies are crucial for managing these conditions.
Purpose of the Study:
- To assess the clinical efficacy and safety of ibutilide for AF and AFl.
- To compare the costs of first-line ibutilide versus electrical cardioversion (EC) from hospital and payer perspectives.
Main Methods:
- Retrospective review of 60 patients treated with ibutilide.
- Efficacy defined by successful conversion and maintenance of sinus rhythm.
- Safety assessed by torsade de pointes incidence.
- Cost analysis from hospital and third-party payer viewpoints.
Main Results:
- Ibutilide achieved 50% conversion and 67% rhythm maintenance until discharge.
- Three patients experienced self-resolving torsade de pointes.
- First-line ibutilide cost more for hospitals ($280 vs. $138 for EC).
- Third-party payers saved $324 per patient with ibutilide ($718 vs. $1042 for EC).
Conclusions:
- Ibutilide's clinical efficacy and safety align with prior trial data.
- Ibutilide is not cost-saving for hospitals but offers savings for payers.
- Cost-effectiveness varies by perspective, highlighting the importance of payer vs. provider economic analysis.